 |
Video: What is a Stock Split?
|
 |
| Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. Co. is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. According to our MTNB split history records, Matinas BioPharma Holdings has had 2 splits. | |
 |

Matinas BioPharma Holdings (MTNB) has 2 splits in our MTNB split history database. The first split for MTNB took place on September 03, 2024. This was a 1 for 50 reverse split, meaning for each 50 shares of MTNB owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 20 share position following the split. MTNB's second split took place on September 28, 2026. This was a 1 for 15 reverse split, meaning for each 15 shares of MTNB owned pre-split, the shareholder now owned 1 share. For example, a 20 share position pre-split, became a 1.33333333333333 share position following the split.
When a company such as Matinas BioPharma Holdings conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the MTNB split history from start to finish, an original position size of 1000 shares would have turned into 1.33333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Matinas BioPharma Holdings shares, starting with a $10,000 purchase of MTNB, presented on a split-history-adjusted basis factoring in the complete MTNB split history.

Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
10/13/2016 |
|
| End date: |
10/09/2026 |
|
| Start price/share: |
$1,380.00 |
|
| End price/share: |
$2.87 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-99.79% |
|
| Average Annual Total Return: |
-46.09% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$20.80 |
|
| Years: |
9.99 |
|
|
 |
| Date |
Ratio |
| 09/03/2024 | 1 for 50 | | 09/28/2026 | 1 for 15 |
|
 |